Diyabet ve Glikasyon
Özet
Dünya genelinde 422 milyon insanı etkileyen diyabet, kronik hiperglisemiye bağlı olarak ciddi organ hasarlarına yol açmaktadır. Bu sürecin temelinde, şekerlerin proteinlere enzimatik olmayan bir şekilde bağlanması olan glikasyon yatmaktadır. Glikasyon süreci; Schiff bazı oluşumuyla başlar, kararlı Amadori ürünlerine (HbA1c, glike albümin gibi) dönüşür ve nihayetinde dokularda birikerek hasara yol açan ileri glikasyon son ürünlerini (AGE'ler) oluşturur. HbA1c, son 8-12 haftalık glisemi kontrolünü yansıtan en yaygın belirteçtir; ancak kronik böbrek yetmezliği, anemiler ve hemoglobin varyantları gibi durumlarda hatalı sonuçlar verebilir. Bu tür kısıtlılıklarda, 1-3 haftalık daha kısa süreli kontrol sağlayan glike albümin ve fruktozamin gibi serum proteinleri tamamlayıcı roller üstlenmektedir. Özellikle glike albümin, obezite ve bazı metabolik hastalıklardan etkilense de diyabet tanısı ve izleminde umut verici bir parametredir. AGE'ler ise sadece vücut içinde oluşmamakta, yüksek ısıl işlem görmüş gıdalarla da alınmakta ve diyabetin mikrovasküler komplikasyonlarının gelişiminde kritik rol oynamaktadır. Sonuç olarak, glike proteinlerin ölçümü diyabet yönetiminde devrim yaratmış olup, bu testlerin standardizasyonu komplikasyonların önlenmesi adına hayati önem taşımaktadır.
Diabetes affects 422 million people worldwide, leading to severe organ damage due to chronic hyperglycemia. At the core of this process lies glycation, the non-enzymatic binding of sugars to proteins. The glycation process begins with the formation of Schiff bases, progresses into stable Amadori products (such as HbA1c and glycated albumin), and ultimately forms advanced glycation end products (AGEs) that accumulate in tissues and cause damage. HbA1c is the most common marker reflecting glycemic control over the past 8-12 weeks; however, it may yield erroneous results in conditions like chronic renal failure, anemias, and hemoglobin variants. In such limitations, serum proteins like glycated albumin and fructosamine, which provide shorter-term control (1-3 weeks), play complementary roles. Specifically, glycated albumin is a promising parameter for diabetes diagnosis and monitoring, although it is affected by obesity and certain metabolic diseases. AGEs are not only formed endogenously but are also introduced into the body through highly heat-processed foods, playing a critical role in the development of microvascular complications of diabetes. In conclusion, the measurement of glycated proteins has revolutionized diabetes management, and the standardization of these tests is vital for preventing complications.
Referanslar
World Health Organisation [Available from: https://www.who.int/health-topics/diabetes#tab=tab_1.
Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014;343:1235681.
Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344 Pt 1:109-16.
Anguizola J, Matsuda R, Barnaby OS, et al. Glycation of human serum albumin. Clin Chim Acta 2013;425:64-76.
Wu WC, Ma WY, Wei JN, et al. Serum Glycated Albumin to Guide the Diagnosis of Diabetes Mellitus. PLoS One 2016;11:e0146780.
Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem 1980;255:3120-7.
Yi L, Swensen AC, Qian WJ. Serum biomarkers for diagnosis and prediction of type 1 diabetes. Transl Res 2018;201:13-25.
Association AD. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1989;12:365-68.
Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-S69.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
Rifai N. Tietz Textbook of Laboratory Medicine Seventh Edition ed Elsevier, 2023.
Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program Steering C. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205-14.
Dagogo-Jack S. Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. Nature Reviews Endocrinology 2010;6:589-93.
Pani LN, Korenda L, Meigs JB, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care 2008;31:1991-96.
Welsh KJ, Kirkman MS, Sacks DB. Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions. Diabetes Care 2016;39:1299-306.
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864-83.
Ahmad J, Rafat D. HbA1c and iron deficiency: a review. Diabetes Metab Syndr 2013;7:118-22.
English E, Idris I, Smith G, et al. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia 2015;58:1409-21.
Cavagnolli G, Pimentel AL, Freitas PA, Gross JL, Camargo JL. Factors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clin Chim Acta 2015;445:107-14.
Kim C, Bullard KM, Herman WH, Beckles GL. Association between iron deficiency and A1C levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999–2006. Diabetes Care 2010;33:780-85.
Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron‐deficiency anemia, non‐iron‐deficiency anemia and HbA1c among adults in the US. J Diabetes 2011;3:67-73.
Camargo JL, Stifft J, Gross JL. The effect of aspirin and vitamins C and E on HbA1c assays. Clin Chim Acta 2006;372:206-9.
Little RR, Rohlfing CL, Tennill AL, et al. Measurement of HbA1c in patients with chronic renal failure. Clin Chim Acta 2013;418:73-76.
Patrinos GP, Giardine B, Riemer C, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 2004;32:D537-41.
Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153-63.
Orts JA, Zuniga A, Bello Y, Fabregat AB, Vicente AI. Hb A1c Determination by Capillary Electrophoresis is an Efficient Method for Detecting β-Thalassemias and Hemoglobin Variants. Hemoglobin 2016;40:335-40.
Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33:2153-63.
Cohen MP. Perspective: measurement of circulating glycated proteins to monitor intermediate-term changes in glycaemic control. Eur J Clin Chem Clin Biochem 1992;30:851-9.
Baker JR, O'Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. Br Med J (Clin Res Ed) 1983;287:863-67.
Roohk HV, Zaidi AR. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J Diabetes Sci Technol 2008;2:1114-21.
Selvin E, Rawlings AM, Grams M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2014;2:279-88.
Sumner AE, Duong MT, Aldana PC, et al. A1C Combined With Glycated Albumin Improves Detection of Prediabetes in Africans: The Africans in America Study. Diabetes Care 2016;39:271-7.
Cohen MP. Clinical, pathophysiological and structure/function consequences of modification of albumin by Amadori-glucose adducts. Biochim Biophys Acta 2013;1830:5480-5.
Priego-Capote F, Scherl A, Muller M, et al. Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010;9:579-92.
Dolhofer R, Wieland OH. Glycosylation of serum albumin: elevated glycosyl-albumin in diabetic patients. FEBS Lett 1979;103:282-6.
Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011;5:1455-62.
Zendjabil M. Glycated albumin. Clin Chim Acta 2020;502:240-44.
Cohen RM, Sacks DB. Comparing multiple measures of glycemia: how to transition from biomarker to diagnostic test? : Oxford University Press; 2012. p. 1615-17.
Giglio RV, Lo Sasso B, Agnello L, et al. Recent updates and advances in the use of glycated albumin for the diagnosis and monitoring of diabetes and renal, cerebro-and cardio-metabolic diseases. Journal of Clinical Medicine 2020;9:3634.
Shima K, Abe F, Chikakiyo H, Ito N. The relative value of glycated albumin, hemoglobin A1c and fructosamine when screening for diabetes mellitus. Diabetes Res Clin Pract 1989;7:243-50.
Araki T, Ishikawa Y, Okazaki H, et al. Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan. Journal of Diabetes Investigation 2012;3:492-97.
Suzuki S, Koga M, Amamiya S, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011;54:2247-53.
Lu L, Pu LJ, Xu XW, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007;40:810-6.
Paradela-Dobarro B, Bravo SB, Rozados-Luis A, et al. Inflammatory effects of in vivo glycated albumin from cardiovascular patients. Biomed Pharmacother 2019;113:108763.
Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun 2020;11:5015.
Vistoli G, De Maddis D, Cipak A, et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013;47:3-27.
Thornalley PJ, Rabbani N. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry—a user's perspective. Biochimica et Biophysica Acta (BBA)-General Subjects 2014;1840:818-29.
Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-16. e12.
Arena S, Salzano AM, Renzone G, D'Ambrosio C, Scaloni A. Non-enzymatic glycation and glycoxidation protein products in foods and diseases: an interconnected, complex scenario fully open to innovative proteomic studies. Mass Spectrom Rev 2014;33:49-77.
Wu Q, Liang Y, Kong Y, et al. Role of glycated proteins in vivo: Enzymatic glycated proteins and non-enzymatic glycated proteins. Food Res Int 2022;155:111099.
Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab 2014;25:15-22.
Rabbani N, Chittari MV, Bodmer CW, et al. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010;59:1038-45.
Sadowska-Bartosz I, Bartosz G. Prevention of protein glycation by natural compounds. Molecules 2015;20:3309-34.
